					010.00141			10/051,770			
	INFO	RMATION DISCLOSUR (Use several sheets if necess			Applicant(s) Glick et al.	_				-	
		Tose several sheets y necess	Filing Date			Group Art Unit					
					January 18, 20	102	1		614		
				U.S. PAT	ENT DOCUMENTS	1			 _		
EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE		NAME	CLASS	SUBCL	ss	FILING IF APPRO		
(5)	t	5,654,281	08/05/1997	Mayer	et al.	1 1					
	2	5,863,927	01/26/1999	Smith e	t al.						
011	1/4										
AUG 0 g		C158						-	EIVE	n	
<u>, </u>	ZUUZ	3 _{J.} ,					חו				
FIRADE	AARMS	}					Al	G 1	4 2002		
				,			TECH (EN'	TER 1600	/2900	
			·		·						
									PAPERS		
							·	IVAL	LTPILEL		
								1			
				FOREIG	N PATENT DOCUMENTS						
	REF	DOCUMENT NUMBER	DATE		COUNTRY	CLASS	SUBCL	ASS	Trans YES	lation NO	
(4)	3	WO 99/17803	04/15/1999	PCT							
,											
_											
						\	{{				
				OTHER	DOCUMENTS (Including	Author, Title	, Date, Pertin	ent Pa	ges, Etc.)		
		1.					<u> </u>				
EXAMINER 2					DATE CONSIDERED	4-31	-03				
EXAMINE	R: Init	al if citation considered, whether	r or not citation is i	n conformar	ice with MPEP Section 609;	Draw line thr	ough citation	if not	in conform	ance and	

Form PTO-A820 (also form PTO-1449)

not considered. Include copy of this form with next communication to applicant.

P09A/REV04

Patent and Trademark Office * U.S. DEPARTMENT OF COMMERCE

		· · · · · · · · · · · · · · · · · · ·	01	13.0	Docket Number (Optional) 010.00141		Applicat	ion Number	051,770	
	INFO	RMATION DISCLOSURI		777	Applicant(s) Glick et al.					
		(Ose severm since sy necess	APR 8 3	2002	Filing Date January 18, 200	02	Group A		1614	
			TRADE	AARIS. PAT	ENT DOCUMENTS					
*EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE		NAME	CLAS	s su	BCLASS	FILING DATE IF APPROPRIATE	
(4)	1	5,965,567	10/12/1999	Archer	et al.	1		1		
)(2	6,211,360	04/03/2001	Glick et	al.					
			·							
		•								
				<u> </u>				}	<u> </u> 	
		P		FOREIG	N PATENT DOCUMENTS				г	
	REF	DOCUMENT NUMBER	DATE	ļ	COUNTRY	CLAS	s s	UBCLASS	YES YES	NO NO
				ļ						
				ļ						
				<u> </u>		·				
				OTHER I	OOCUMENTS (Including)	Author, Tit	le, Date, P	ertinent Pa	ges, Etc.)	
\ \ <u>\</u>	$\Big] \Big $	Murray et al., "Interac Sci., 34:1899-1911 (198	ction of Dextrorot 84)	ary Opioid	s with Phencyclidine Reco	gnition Si	tes in Ra	t Brain M	lembranes,	" <u>Life</u>
(3	Nishikawa et al., "Evidence for, and Nature of, the Tonic Inhibitory Influence of Habenulointerpeduncular Pathways upon Cerebral Dopaminergic Transmission in the Rat," Brain Res., 373:324-336 (1986)							s upon		
EXAMINE	R	21			DATE CONSIDERED 7	-3/-	ფ			
EXAMINE not conside	R: Initi	ial if citation considered, whether	r or not citation is it t communication to	n conforman applicant.	ce with MPEP Section 609; D	raw line tl	hrough cit	ation if no	t in conform	ance and
										

Form PTO-A820 (also form PTO-1449) P09A/REV04

Patent and Trademark Office * U.S. DEPARTMENT OF COMMERCE

Application Number

	••	OIPE	Docket Number (Optional) 010.00141	Application Number 10/051,770					
IN		ATION DISCLOSURE CITATION (Use several sheets if necessary)	Applicant(s) Glick et al.						
			Filing Date January 18, 2002	Group Art Unit 1614					
*EXAMINER			e, Date, Pertinent Pages, Etc.)						
INITIAL	5	Koyuncuoglu et al., "The Treatment of Heroin Addicts with Dextromethorphan: A Double-blind Comparison of Dextromethrophan with Chlorpromazine," Int. J. Clin. Pharmacol. Ther., 28:147-152 (1990)							
6)	6	Glick et al., "Effects and Aftereffects of Ibogaine on 195:341-345 (1991)	Morphine Self-administration in Ra	s," Europ. J. Pharmacol.,					
8	7	Flores et al., "A Subtype of Nicotinic Cholinergic Receptor in Rat Brain Is Comprised of 4 and 2 Subunits and Is Up-regulated by Chronic Nicotine Treatment," Mol. Pharmacol., 41:31-37 (1992)							
	8	Koyuncuoglu, "The Combination of Tizanidine Man Addicted Outpatients," Int. J. Clin. Pharmacol. The	rkedly Improves the Treatment with er., 33:13-19 (1995)	Dextromethorphan of Heroin					
(E)	9	Popik et al., "NMDA Antagonist Properties of the P 275:753-760 (1995)	utative Antiaddictive Drug, Ibogaine	" J. Pharmacol. Exp. Ther.,					
(5)	10	Sweetnam et al., "Receptor Binding Profile Suggest: Anti-addictive Activity," <u>Psychopharmacology</u> , 118:	s Multiple Mechanisms of Action Are 369-376 (1995)	Responsible for Ibogaine's Putative					
6	11	Chen et al., "Ibogaine Block of the Nmda Receptor:	in Vitro and in Vivo Studies," <u>Neuro</u>	pharmacology, 35:423-431 (1996)					
6	12	Glick et al., "18-Methoxycoronaridine, a Non-toxic Self-administration and on Mesolimbic Dopamine R	Iboga Alkaloid Congener: Effects on elease in Rats," <u>Brain Res</u> ., 719:29-3	Morphine and Cocaine 5 (1996)					
4	13	Badio et al., "Ibogaine: A Potent Noncompetitive Blocker of Ganglionic/Neuronal Nicotinic Receptors," Molec. Pharmacol., 51:1-5 (1997)							
(3)	14	Pulvirenti et al., "Dextromethorphan Reduces Intra 321:279-283 (1997)	venous Cocaine Self-administration i	n the Rat," <u>Eur. J. Pharmacol.</u> ,					
3	15	Rezvani et al., "Attenuation of Alcohol Consumption by a Novel Non-toxic Ibogaine Analog (18-Methoxycoronaridine) in Alcohol Preferring Rats," Pharmacol. Biochem. Behav., 58:615-619 (1997)							
(b)	16	Ebert et al., "Opioid Analgesics as Noncompetitive in 56:553-559 (1998)	N-methyl-d-aspartate (NMDA) Antag	onists," <u>Biochem. Pharmacol.,</u>					
EXAMINER		À	DATE CONSIDERED						
		/ // /I	7-31-5						

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

· V		OIPE	Docket Number (Optional) 010.00141	Application Number 10/051,770					
INFORMATION DISCLOSURE CITATION Applicant(s)									
	,	(Use several sheets if necessary) APR 8 3 2002	Glick et al.	Group Art Unit					
			January 18, 2002	1614					
*EXAMINER OTHER DOCUMENTS (Inclase Date, Pertinent Pages, Etc.)									
		Glick et al., "Mechanisms of Anti-addictive Actions	of Ibogaine," Ann. N.Y. Acad. Sci., 8	344, 214-226 (1998)					
6	W 17								
8	18	Mah et al., "Ibogaine Acts at the Nicotinic Acetylcholine Receptor to Inhibit Catecholamine Release," Brain Res., 797:173-180 (1998)							
	19	Fryer et al., "Noncompetitive Functional Inhibition at Diverse, Human Nicotinic Acetylcholine Receptor Subtypes by Bupropion, Phencyclidine, and Ibogaine," <u>J. Pharmacol. Exp. Ther.</u> , 288:88-92 (1999)							
(3)	20	Lukas et al., "International Union of Pharmacology. XX. Current Status of the Nomenclature for Nicotinic Acetylcholine Receptors and Their Subunits," Pharmacol. Rev., 51:397-401 (1999)							
(h)	21	Maisonneuve et al., "Attenuation of the Reinforcing Efficacy of Morphine by 18-Methoxycoronaridine," Europ. J. Pharmacol., 383:15-21 (1999)							
(3)	22	Quick et al., " 3 4 Subunit-containing Nicotinic Receptors Dominate Function in Rat Medial Habenula Neurons," Neuropharmacology, 38:769-783 (1999)							
(3)	23	Reid et al., "A Nicotinic Antagonist, Mecamylamine, Reduces Cue-induced Craving in Cocaine-dependent Subjects," Neuropsvchopharmacology, 20:297-307 (1999)							
4	24	Glick et al., "18-MC Reduces Methamphetamine an (2000)	d Nicotine Self-administration in Rat	s," <u>NeuroReport,</u> 11:2013-2015					
4	25	Glick et al., "18-Methoxycoronaridine (18-MC) and Ibogaine: Comparison of Anti-addictive Efficacy, Toxicity and Mechanisms of Action," Ann. N.Y. Acad. Sci., 914:369-387 (2000)							
8)	26	Glick et al., "Development of Novel Medications for Drug Addiction: The Legacy of an African Shrub," Ann. N.Y. Acad. Sci., 909:88-103 (2000)							
4	27	Hernandez et al., "Dextromethorphan and its Metabolite Dextrorphan Block 3 4 Neuronal Nicotinic Receptors," J. Pharmacol. Exp. Ther., 293:962-967 (2000)							
(3)	28	Jun et al., "Dextromethorphan Alters Methampheta 67:405-409 (2000)	nmine Self-administration in the Rat,'	' <u>Pharmacol. Biochem. Behav.,</u>					
EXAMINER		A 1	DATE CONSIDERED						
		-/3\	7-31-9						
*EXAMINER: I	nitial if	citation considered, whether or not citation is in conformat		rough citation if not in conformance and					

P09B/REV04

not considered. Include copy of this form with next communication to applicant.

(Docket Number (Optional) 010.00141 10/051,770
INF	ORM	ATION DISCLOSURE CITATION SApplicant(s)
		(Use several sheets if necessary) APR: 0 3 7007 Glick et al. Group Art Unit January 18, 2002 1614
*EXAMINER		OTHER DOCUMENTS (Inchange Race), Title, Date, Pertinent Pages, Etc.)
2	29	Levin et al., "Mecamylamine Preferentially Inhibits Cocaine Versus Food Self-administration in Rats," Soc. Neurosci. Abstr., 26:1821 (2000)
(2)	30	Glick et al., "Comparative Effects of Dextromethorphan and Dextrorphan on Morphine, Methamphetamine, and Nicotine Self-administration in Rats," <u>Europ. J. Pharmacol.</u> , 422:87-90 (2001)
(3)	31	Klink et al., "Molecular and Physiological Diversity of Nicotinic Acetylcholine Receptors in the Midbrain Dopaminergic Nuclei," J. Neurosci., 21:1452-1463 (2001)
B	32	Papke et al., "Analysis of Mecamylamine Steroisomers on Human Nicotinic Receptor Subtypes," J. Pharmacol. Exp. Ther., 297:646-656 (2001)
EXAMINER	1	DATE CONSIDERED 7-31-9

P09B/REV04

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and

not considered. Include copy of this form with next communication to applicant.